Mr. Craig MacPhail reports

NUMINUS WELLNESS ANNOUNCES CORPORATE UPDATE

Michael Tan has been appointed chief executive officer of Numinus Wellness Inc., with Payton Nyquvest transitioning to the role of executive chair.

Mr. Tan has been appointed chief executive officer of the company, succeeding Mr. Nyquvest, who will transition to the role of executive chair. Mr. Tan joined Numinus as chief operating officer in 2019, prior to its initial listing, and added the role of president to his responsibilities in 2022. Over the years, he has overseen the company's operations, merger-and-acquisition activities, and organizational realignments. In his new role, Mr. Tan will prioritize strengthening Numinus's clinical research and practitioner training programs while aligning the company's focus to better address emerging opportunities in mental health care. Before joining Numinus, Mr. Tan held senior leadership positions at organizations, including the B.C. Liquor Distribution Branch, Hudson's Bay, Saks Fifth Avenue and UPS.

"I am committed to leading Numinus forward and pursuing opportunities for growth where we can create meaningful impact," said Mr. Tan. "Our efforts will remain focused on advancing the areas of the business that show the most promise."

In his new role as executive chair, Mr. Nyquvest will continue to play an active role in the company, focusing on informing on corporate strategy, investor relations and strategic partnerships. As a pioneer in the psychedelic therapy sector, Numinus will benefit from his extensive experience, network and corporate finance acumen.

"As I transition from CEO to executive chair, I look forward to supporting the leadership team and contributing to the company's ongoing priorities," added Mr. Nyquvest.

The company also announced that Allen Morishita has resigned from its board of directors. Mr. Morishita has served on the board since Numinus's inception, and the company thanks him for his expert guidance and counsel.

About Numinus Wellness Inc.

Numinus helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model -- technology-driven clinic support, clinical trial research and comprehensive practitioner training -- is at the forefront of a transformation aimed at healing rather than managing symptoms of depression, anxiety, trauma, pain and substance use. At Numinus, it is leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

We seek Safe Harbor.